Publicaciones en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (48)

2024

  1. Controversies in the management of anti-TNF therapy in patients with Crohn's disease: a Delphi consensus

    BMJ Open Gastroenterology, Vol. 11, Núm. 1

2023

  1. Akkermansia deficiency and mucin depletion are implicated in intestinal barrier dysfunction as earlier event in the development of inflammation in interleukin-10-deficient mice

    Frontiers in Microbiology, Vol. 13

  2. Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  3. Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn's disease

    Biomedicine and Pharmacotherapy, Vol. 159

  4. Transmural or mucosal healing in Crohn´s disease. Which is the goal to be pursued?

    Revista espanola de enfermedades digestivas, Vol. 115, Núm. 6, pp. 289-291

2022

  1. Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare

    Frontiers in Immunology, Vol. 13

  2. Lentinula edodes extract increases goblet cell number and Muc2 expression in an intestinal inflammatory model of Trichinella spiralis infection

    Biomedicine and Pharmacotherapy, Vol. 150

2021

  1. Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  2. Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels

    Alimentary Pharmacology and Therapeutics, Vol. 54, Núm. 8, pp. 999-1012

2020

  1. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596

2019

  1. Characteristics of inflammatory bowel disease in patients of Roma/Gypsy ethnicity. A case-control study

    Digestive and Liver Disease, Vol. 51, Núm. 5, pp. 669-674

  2. Endoscopic follow-up and therapeutic attitude after ileocolonic resection in a nationwide Spanish cohort of Crohn’s disease patients: the Practicrohn study

    Expert Review of Gastroenterology and Hepatology, Vol. 13, Núm. 8, pp. 807-813

  3. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

    Therapeutic Advances in Gastroenterology, Vol. 12

  4. Metabolic bone disease in patients diagnosed with inflammatory bowel disease from Spain

    Therapeutic Advances in Gastroenterology, Vol. 12

  5. Transition Care Program of Adolescents With Inflammatory Bowel Disease: Perceptions From A Survey for Patients

    Inflammatory bowel diseases, Vol. 25, Núm. 3, pp. e22-e23

2018

  1. Reviewing the therapeutic role of budesonide in Crohn's disease

    Gastroenterologia y Hepatologia

2016

  1. Etiopatogenia: nexos en común entre la hidradenitis supurativa y la enfermedad de Crohn

    Actas Dermo-Sifiliograficas, Vol. 107, pp. 13-20

2015

  1. A new role for reticulon-4B/NOGO-B in the intestinal epithelial barrier function and inflammatory bowel disease

    American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 308, Núm. 12, pp. 981-993

  2. Incidence, management, and course of cancer in patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 9, Núm. 4, pp. 326-333

  3. Weber-Christian disease with ileocolonic involvement successfully treated with infliximab

    World Journal of Gastroenterology, Vol. 21, Núm. 17, pp. 5417-5420